ArticleScientific reports2025
Serum LncRNA PSMB8-AS1 as a novel biomarker for predicting acute coronary syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent basic research has shown that Long non-coding RNA PSMB8-AS1 can promote the progression of atherosclerosis. The primary aim of this study was to investigate whether serum PSMB8-AS1 levels can predict acute coronary syndrome (ACS) in patients with chest pain. A total of 109 chest pain patients excluded from coronary artery disease (CAD), and 172 ACS patients, were enrolled from our center. Logistic regression analysis was performed to construct predictive models using traditional cardiovascular risk factors and then combined with PSMB8-AS1. Receiver operating characteristic (ROC) analysis was used to evaluate the predictive ability of these models. Additionally, an external validation cohort, including 15 non-CAD chest pain patients and 26 ACS patients, was used for validation. Serum PSMB8-AS1 levels were significantly higher in ACS patients compared to non-CAD patients. After adjusting for traditional risk factors, PSMB8-AS1 was independently associated with ACS (Adjusted OR = 3.826, 95% CI 2.321-6.305, P < 0.001). ROC analysis indicated that the model incorporating PSMB8-AS1 significantly improved the predictive ability for ACS compared to the traditional risk factor-based model (AUC: 0.785 vs 0.705, DeLong test P = 0.0036). Importantly, these findings were validated in the external cohort. PSMB8-AS1 could serve as a novel biomarker for predicting acute coronary syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.